Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Liver Cirrhosis

Liver Cirrhosis Clinical Trial

Official title:

Fractional Excretion of Urea: an Excellent Simple Tool for the Differential Diagnosis of Acute Kidney Injury in Liver Cirrhosis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03675633
• Other study ID #: FEUrea in liver cirrhosis
• Status: Not yet recruiting
• Start date: May 1, 2021
• Est. completion date: January 31, 2022

Study information

• Verified date: February 2021
• Source: Assiut University
• Contact: Nermeen Mobarez, specialist
• Phone: 00201098800485
• Email: nermeenmobarez[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to evaluate the diagnostic performance of FEUrea for the differential diagnosis of AKI in patients with cirrhosis and ascites Specifically, the ability of FEUrea to distinguish between ATN versus Pre renal azotemia and HRS.

Description:

AKI according to KDIGO guidelines is defined as the followings: - An increase in serum creatinine by ≥0.3 mg/dl (≥26.5 µmol/l) within 48 h - An increase in serum creatinine to ≥1.5 times baseline within the previous 7 days - Urine volume ≤0.5 ml/kg/h for 6 h Serum creatinine overestimates renal function in cirrhotic patients due to a number of factors: Creatinine production in patients with cirrhosis is reduced due to muscle wasting, there is an increased secretion of creatinine in the renal tubules, sCr may be diluted due to an increased volume of distribution, and finally, high bilirubin levels may interfere with the assays to measure its level. Recently, the International Club of Ascites (ICA) has adopted the concept of AKI which was developed originally to be used in general critically-ill patients. AKI is defined as the increase of at least 0.3 mg/dL (26 μmol/L) and/or ≥ 50% from baseline, within 48 hours Since urea absorption is largely modulated in the proximal tubules, it is not affected by diuretics acting more distally. The investigators therefore hypothesized that the fractional excretion of urea (FEUrea) could serve as a clinical aid in making an early distinction between ATN versus Pre renal azotemia and HRS type 1 in patients with cirrhosis and ascites presenting with AKI Fractional excretion of urea (FEUrea) ([urine urea nitrogen/ blood urea nitrogen)/(urine creatinine/plasma creatinine)] X 100) < 35% is specific for prerenal azotemia, and > 50% is specific for ATN

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: January 31, 2022
• Est. primary completion date: December 31, 2021
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Liver cirrhosis of any etiology diagnosed by clinical parameters involving laboratory tests, endoscopic or radiologic evidence of cirrhosis,
• History of decompensation (hepatic encephalopathy, ascites, variceal bleeding, jaundice)
• Age greater than 18 years
• Presence of moderate or severe ascites Exclusion Criteria: Patients excluded from analysis were those who did not meet inclusion criteria as well as the following
• Prior liver or kidney transplant,
• Advanced chronic kidney disease G4(GFR category grade 4) according to KDIGO guidelines.
• Patients on acute or chronic renal replacement therapy,
• Ambiguous diagnosis of AKI and phenotype of AKI,
• Patients with hepatocellular carcinoma.

Related Conditions & MeSH terms

• Acute Kidney Injury
• Fibrosis
• Liver Cirrhosis

Intervention

Diagnostic Test:
• FEUrea
FEUrea in decompansated liver cirrhosis

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (3)

Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017 May;5(2):127-137. doi: 10.1093/gastro/gox009. Epub 2017 Apr 24. — View Citation

Durand F, Olson JC, Nadim MK. Renal dysfunction and cirrhosis. Curr Opin Crit Care. 2017 Dec;23(6):457-462. doi: 10.1097/MCC.0000000000000457. Review. — View Citation

Piano S, Brocca A, Angeli P. Renal Function in Cirrhosis: A Critical Review of Available Tools. Semin Liver Dis. 2018 Aug;38(3):230-241. doi: 10.1055/s-0038-1661372. Epub 2018 Jul 24. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	comparison of FEUrea in different types of AKI in liver cirrhosis	measurement of FEUrea in different types of AKI in decompansated liver cirrhosis to identify its cause	baseline